Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EUDA
EUDA logo

EUDA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy EUDA Health Holdings Ltd (EUDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
15.200
1 Day change
1.20%
52 Week Range
86.000
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

EUDA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is in a weak technical position, has no positive short-term catalysts, no supportive proprietary trading signals, and no recent news or analyst momentum to justify an immediate entry. Given the current data, the better decision is to avoid buying now.

Technical Analysis

EUDA is showing a bearish trend. The MACD histogram is negative and expanding, indicating downside momentum is strengthening. The moving averages are bearish, with SMA_200 above SMA_20 above SMA_5, which confirms a downtrend. RSI_6 at 27.851 is near oversold territory, but it is not yet giving a strong reversal signal. Price at 15.02 is below the pivot of 16.604 and only slightly above support at S1 15.242, with S2 at 14.4 as the next downside level. The stock trend model also points to weakness, with a 70% chance of -0.7% next day and -4.49% over the next month.

Positive Catalysts

  • No recent news in the last week, no significant hedge fund accumulation, no insider buying trend, no AI Stock Picker signal, and no SwingMax signal. There are no clear positive catalysts in the current dataset.

Neutral/Negative Catalysts

  • The stock is down 3.10% on the session, technical indicators remain bearish, and the trend model projects further weakness over the next month. Hedge funds and insiders are neutral, congress trading data is unavailable, and there is no recent news to support a rebound.

Financial Performance

Latest quarter financials are not available because the financial snapshot returned an error. As a result, there is no confirmed evidence of recent revenue or earnings growth to support a long-term investment decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend or consensus signal to support buying. Based on the available information, Wall Street support appears absent or insufficient.

Wall Street analysts forecast EUDA stock price to rise
Analyst Rating
0
Wall Street analysts forecast EUDA stock price to rise
Buy
Hold
Sell
0
Current: 15.020
sliders
Low
0
Averages
0
High
0
0
Current: 15.020
sliders
Low
0
Averages
0
High
0
Greenridge
William Gregozeski
Buy
downgrade
$6
AI Analysis
2026-03-09
Reason
Greenridge
William Gregozeski
Price Target
$6
AI Analysis
2026-03-09
downgrade
Buy
Reason
Greenridge analyst William Gregozeski lowered the firm's price target on EUDA Health to $2.75 from $6 and keeps a Buy rating on the shares. The firm updated its model for a reduction of Helixe bottles sold in 2026, decreasing to 50,000 from 105,000, which reduced its revenue estimate to $27.23M from $43.05M. It also added in the 12.5M shares that were issued in late February, which had a dilutive effect on its EPS estimates, the analyst tells investors.

People Also Watch